Some investigators have recommended using a weighted composite end point to address these concerns in which individual components are valued relative to one another. 4, 5, 7, 8 However, data to inform the weighting of individual end points, using opinions from both clinical trial authors and patients, have not been collected. Furthermore, prior efforts to weigh composite end points have assumed that patients, physicians, and clinical trialists would assign similar values to individual events (eg, severity of stroke relative to death). If patients value individual components of a composite end point differently from trialists, this would suggest that efforts to develop weighted composite end points may also need to address patient preferences. Accordingly, we asked both patients and clinical trialists to weigh the relative importance of frequently measured outcomes from cardiovascular clinical trials. To better understand the value of each end point for patients and trialists, we quantified the relative severity of each end point compared with death and assessed for rating differences between the 2 groups. In addition, we examined whether end point weights varied by the demographic and clinical characteristics of patients and trialists.
C
linical trials frequently use a composite primary end point to increase event rates, to improve trial efficiency, and to decrease study costs. [1] [2] [3] However, analytic approaches to composite end points typically assume that the individual components are of similar importance. In practice, a treatment often has different effects on each individual end point, resulting in uncertainty when the results of a clinical trial are interpreted with the use of a composite primary end point.
holding areas, at various times of day, over a 3-month recruiting period. After providing verbal consent, subjects anonymously completed the survey described below. The survey was personally administered by a member of the research team, and explanations of the assignment of end point weights (ie, sum of 25 points) were provided as needed.
Selection of Trialists
In parallel with the patient survey, an identical electronic survey was administered to authors of major randomized, clinical trials of statin lipid-lowering drugs and coronary revascularization therapies published in the English language literature between 2000 and 2009. Potential clinical trials were identified through Medline searches, literature review, and the ClinicalTrials.gov Web site (http://www.clinicaltrials.gov; see Tables I and II in the online-only Data Supplement). Only investigators from trials with clinical end points were included in this survey; trials with surrogate marker end points (eg, lipid levels, ultrasound or computed tomography findings, angiographic late loss after coronary intervention) were not included. E-mail addresses were collected from Medline and Internet browser searches by the study investigators and stored in a secure database, after which an invitation was sent via e-mail with links to participate or to decline participation. Each clinical trialist was only permitted to complete the survey once, even if listed as an author on multiple clinical trials.
Survey Data Collection
The text of the survey is illustrated in Figure 1 . Although demographic and clinical data collected were specific to patients and trialists, the same survey for weighing clinical outcomes was administered to both groups. Each respondent was asked to distribute 25 "spending weights" among 5 clinical outcomes commonly included in composite primary end points of clinical trials of statins and coronary revascularization: death, myocardial infarction (MI), stroke, coronary revascularization, and hospitalization for angina. All respondents were required to distribute exactly 25 weights across the 5 end points, and verification of the 25-point total was ensured before the survey could be submitted. To minimize bias, the specific order of the 5 individual end points to be weighed was varied at random for both patients and trialists.
Analytic Approach
To facilitate interpretation as percentages, we rescaled the data so that the weights sum to 100. We then converted each respondent's end point weights to ratios by dividing the weight assigned to each nonfatal end point (MI, stroke, revascularization, and hospitalization) by the weight assigned to mortality. These ratios represent the relative unadjusted weights assigned to each of the 4 nonfatal end points versus the reference of death. For example, a respondent who assigned values of 10, 5, 5, 3, and 2 points for death, MI, stroke, revascularization, and hospitalization, respectively, would have end point ratios of Figure 1 . Survey for weighing clinical end points. The order of individual end points was varied at random to help minimize bias when end point weights were assigned.
by guest on July 25, 2017 http://circ.ahajournals.org/ Downloaded from 0.5, 0.5, 0.3, and 0.2 for MI, stroke, revascularization, and hospitalization relative to death.
We then assessed whether the weights assigned by trialists differed from those of patients. Because the weights represent a special type of multivariate data known as compositional data, which are constrained to add up to a constant value (ie, 25 points), 9 we used multivariate methods appropriate for multiple correlated dependent variables. This constant-sum constraint imposes a mathematical structure to the data (an increase in 1 variable mathematically necessitates a decrease in another) for which standard statistical methods are not appropriate. To accomplish this, the 4 end point ratios for each participant were log transformed and analyzed with the use of standard repeated-measures ANOVA models. This model included a fixed effect for respondent type (patient or trialist), a respondent type-by-end point interaction term, and an unstructured residual covariance matrix to account for differing variances and within-respondent correlations among the 4 variables.
Next, we conducted analyses to examine the association between respondent characteristics and end point weights separately for patients and trialists. Continuous characteristics (eg, age) were categorized so that predicted mean weights could be displayed for each category. We first analyzed each respondent characteristic individually in unadjusted models, similar to that described above. Next, we fit a multivariable model including all respondent characteristics and performed backward selection (P<0.05) to retain only those characteristics that were associated with end point weights.
For responses in which a specific end point was assigned a weight of 0 (eg, 0 points assigned to revascularization by an individual patient or trialist), we replaced the 0 with a uniform random positive fractional weight <0.5 to avoid mathematical difficulties in calculating log ratios. This assumes that a reported weight of 0 was a "detection limit" error resulting from the coarseness of the response scale (0-25), ie, that respondents would have given at least some nominal positive weight to the end point if a large enough number of spending points were available. To account for the uncertainty in these replaced values, we used multiple imputation methods. Specifically, we repeated the zero-replacement process 25 times, generating 25 distinct complete data sets. All analyses described above were replicated on each of the 25 data sets, and the results from each were pooled to obtain final estimates for statistical inferences. This approach allows calculation of end point log ratios for all respondents and appropriately incorporates uncertainty resulting from imputation.
All analyses were performed with SAS version 9.3 (SAS Institute, Inc, Cary, NC) and R version 2.10.0 (R Foundation for Statistical Computing, Vienna, Austria). For each analysis, we evaluated the null hypothesis at a 2-sided significance level of 0.05. Findings are reported as mean (interquartile range). The study protocol was reviewed and approved by the Institutional Review Board of Saint Luke's Hospital.
Results

Comparison Between Patients and Trialists
A total of 785 patients and 164 clinical trialists completed the study survey, representing response rates of >95% of patients solicited and ≈60% of trialists with valid e-mail addresses. Overall, there were marked differences (P<0.001) in how patients and clinical trialists weighed the relative severity of each end point compared with death (Table 1) . In general, patients assigned slightly higher importance to MI and stroke as death (end point ratios, 1.12 and 1.08, respectively) and viewed repeat revascularization and hospitalization as significantly less severe than death (end point ratios, 0.48 and 0.28, respectively). In contrast, clinical trialists assigned one third and one half as much importance to MI or stroke (end point ratios, 0.63 and 0.53, respectively) than death, and they weighed repeat revascularization and hospitalization as relatively minor events (end point ratios, 0.20 and 0.13, respectively).
Patient Subgroups
End point weights for patient subgroups are summarized in Table 2 . Overall, 54% of patients were male, 84% were white, and more than half were ≥65 years of age. Nearly 60% had a college or graduate degree; 55% were retired; and two thirds were currently married. More than two thirds of patients had hypertension or hypercholesterolemia; 1 in 4 had a prior MI; 1 in 3 had undergone prior percutaneous coronary intervention; and 1 in 6 had undergone prior coronary artery bypass grafting.
Although patients in aggregate assigned weights of relatively similar importance for MI and stroke compared with death, there were differences by age, race, and household income level. Patients <45 years of age weighed death as twice as severe as MI or stroke, whereas older patients (65-74, 75-84, and ≥85 years of age) assigned greater importance to avoiding MI or stroke than death (P<0.001 across age categories; see Table 2 ). Patients between 45 and 64 years of age viewed death, MI, and stroke as equally severe. African-American patients were more concerned about MI than either stroke or death, whereas white patients were equally concerned about death, stroke, and MI (P=0.01 for comparison between races). Patients with household incomes <$40 000 annually were more concerned about MI and stroke than death, whereas those with annual household incomes >$120 000 were most concerned about death and assigned significantly less importance to revascularization (P=0.001). There were no differences in weighting assignments by other clinical and socioeconomic subgroups such as marital status, education level, and employment status or by medical comorbidity. These findings were similar in fully adjusted models (Figure 2 ).
Clinical Trialist Subgroups
End point weights for clinical trialist subgroups are displayed in Table 3 . Among 164 clinical trialists, 93% were practicing in academic settings, and 70% were ≥20 years out of training. One half of the trialists were European, whereas another 39% were American. Nearly three quarters of the trialists were In unadjusted analyses, clinical trialists who spent most of their time in clinical care were more likely to weigh death as more severe than stroke or MI (see Table 3 ). There were also differences by cardiovascular subspecialty in how trialists weighed the relative severity of death versus MI and stroke. However, these differences were no longer significant after adjustment for physician characteristics (data not shown; all P>0.05), which suggests less variation in the weighing of clinical end points among trialists compared with variation in weighing among patients.
Discussion
Despite the common practice of weighing all adverse events equally within a composite end point of a clinical trial, we found that patients and clinical trial authors considered "hard" cardiovascular events (death, MI, stroke) significantly more important than repeat revascularization or hospitalization for angina. Moreover, among hard clinical end points, the relative value varied substantially between patients and trialists. Clinical trialists placed greater emphasis on avoiding death than MI or stroke, whereas patients viewed avoiding death, stroke, and MI as equally severe. Furthermore, there was heterogeneity in how patients weighed clinical end points according to age, race, and household income. Collectively, our findings provide important insights into how clinical trialists and patients prioritize the goals of medical treatment.
For >2 decades, clinical trialists have struggled with the inadequacy of composite end points. Ideally, the components of the composite should have similar importance, frequency of occurrence, and response to the therapy being tested. 4 However, these criteria are seldom met, and the clinical significance of individual end points within the composite can vary considerably. 5 Not infrequently, trial results are driven by the impact of therapy on a single component outcome, often representing an event of much lesser severity (eg, revascularization or rehospitalization) than hard end points such as death. For example, recurrent ischemia was primarily responsible for the reduction in the composite end points in 1 statin trial, whereas mortality was completely unaffected by randomization to statin therapy. 10 Similarly, repeat revascularization drove the difference in the composite end point in multiple clinical trials comparing percutaneous coronary intervention with coronary artery bypass grafting for multivessel coronary artery disease, with no differences in hard end points like mortality and MI. [11] [12] [13] To address these concerns, some authors have recommended a system of weighing composite end points. In 1989, Califf et al 3 surveyed 407 cardiologists at a national specialty conference to assign rank order to a list of end points, although this process did not quantify the relative severity of 1 end point relative to another. In 1992, Braunwald et al 14 assigned weights to death (1 point), disabling intracranial hemorrhage (1 point), heart failure (0.8 points), major bleeding (0.3 points), and other adverse events on the basis of clinical importance or severity. The authors acknowledged the arbitrary nature of their weights and recommended continued refinement of these scores in the future.
Other studies have also attempted to provide relative values to different end points by using arbitrary systems of assigning weights, by surveying clinical researchers to arrive at consensus weights, [15] [16] [17] [18] [19] [20] [21] [22] [23] or by using disability-adjusted life-years to estimate the importance of end points to patients. 24, 25 In addition, several studies have elicited patient and physician preferences about CABG indicates coronary artery bypass surgery; Hosp, hospitalization for angina; MI, myocardial infarction; PCI, percutaneous coronary intervention; and Revasc, coronary revascularization procedure.
*Mean end point weights may not add exactly to 100 because of rounding, and total number in each subgroup may not add to 785 patients because of differential response rates for each question.
†P value for comparison of end point weights across categories of each characteristic. stroke prophylaxis in atrial fibrillation or the threshold at which a patient would be willing to consider systemic anticoagulation to avoid suffering a stroke. [26] [27] [28] One recent evaluation of patients used an online survey to confirm the lack of equal weighing in composite end points, and these authors recommended further emphasis on weighing individual adverse events to improve statistical validity and interpretation of clinical trial results. 29 Our study expands these findings by evaluating weights by both clinical trialists and cardiovascular patients. To the best of our knowledge, no other studies have solicited patient input on the relative severity of individual cardiovascular end points.
By surveying clinical trialists with the same clinical end points as the ones they used in their respective statin and coronary revascularization trials, we were able to generate relative weights for each individual end point compared with death. It is important to note that both the clinical trialists and the patients apportioned different weights to death compared with stroke and MI. These differences were especially prominent among older patients; stroke and MI were viewed as ≈50% more important than death in those individuals 75 to 84 years of age and 150% to 250% more important than death in those ≥85 years of age. Similarly, patients with low household income were more concerned about revascularization than those with higher household income and thus placed at least as much, if not more, importance on avoiding MI and stroke than avoiding death. Of note, these observed differences in patients' end point weights by age, race, and income persisted after adjustment for potential confounders such as education, marital and employment status, and other demographic and clinical variables. Differences between physicians and patients and among patients themselves suggest that the development of weighted composite outcomes is complex and requires further study to help determine whether trialist, patient, or both patient and trialist preferences are needed in the development of end point weights for future clinical trials.
Study Limitations
The findings from our study should be interpreted in the context of several potential limitations. First, the patients included in the survey of this study were followed at a single-specialty cardiovascular practice, and results may not be generalizable to all patients. Second, the short period of time available for surveying patients waiting for office visits or procedures generally precluded a comprehensive discussion of the definitions of specific adverse events. For instance, the manifestations of MI could range from minor elevations in myocardial enzymes to cardiogenic shock. Because prior studies have not shown that patients rate MI as worse than death or similar to stroke, this difference could have occurred as a result of the brevity of our survey form and time of patient interaction. As a result, differences in baseline definitions of the end points between trialists and patients may have affected our comparisons of end point weights between the 2 groups. However, if such differences are present, they further reinforce the fact that these events have different significance between patients and trialists. Third, although our focus was on surveying trialists because they are directly involved in clinical trial design, we did not survey physicians in daily clinical practice. Fourth, we focused our analyses on efficacy end points and did not assess the importance of safety end points such as bleeding because these are not typically included as part of a composite primary end point. Finally, although we derived weights for individual components of a composite end point, a systematic approach to weighing composite end points requires further study, especially given the differences identified between trialists and patients. Hosp indicates hospitalization for angina; MI, myocardial infarction; and Revasc, coronary revascularization procedure *Mean end point weights may not add exactly to 100 because of rounding, and total number in each subgroup may not add to 164 trialists because of differential response rates for each question.
†P value for comparison of end point weights across categories of each characteristic. ‡Trialist specialty was self-designated by each respondent. Invasive cardiologists are trained in general cardiology and are qualified to perform cardiac catheterization and diagnostic angiography. Interventional cardiologists are qualified to perform both the diagnostic procedures and a variety of more invasive measurements (eg, intracoronary pressure or ultrasound assessments) and percutaneous therapies (eg, coronary and peripheral arterial revascularization, valvuloplasty, repair of vascular and intracardiac defects). by guest on July 25, 2017 http://circ.ahajournals.org/ Downloaded from
